Characteristics of NSCLCs harboring NRAS mutations.
Kadoaki Ohashi
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
Martin Sos
No relevant relationships to disclose
Xi Chen
No relevant relationships to disclose
Charles M. Rudin
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Maria E. Arcila
No relevant relationships to disclose
Christine Marie Lovly
No relevant relationships to disclose
Cindy L Vnencak-Jones
No relevant relationships to disclose
Hidefumi Sasaki
No relevant relationships to disclose
Dora Dias-Santagata
Consultant or Advisory Role - Bio-Reference Laboratories
Steven M. Dubinett
Consultant or Advisory Role - Tagara Pharmaceuticals
Gregory J. Riely
Consultant or Advisory Role - Abbott Laboratories; ARIAD; Chugai Pharma; Daiichi Sankyo; Taragara
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck; Pfizer
Marc Ladanyi
No relevant relationships to disclose
Wilbur A. Franklin
No relevant relationships to disclose
Mark G. Kris
Consultant or Advisory Role - Boehringer Ingelheim; Pfizer
Research Funding - Boehringer Ingelheim; Pfizer
D. Ross Camidge
No relevant relationships to disclose
Paul A. Bunn
Employment or Leadership Position - IASLC; Univ. of Colorad
Consultant or Advisory Role - Agennix; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; GlobeImmune; Lilly; Merck; Merrimack; Novartis; OSI Pharmaceuticals; Pfizer; Roche/Genentech; Sanofi
Honoraria - Agennix; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; GlobeImmune; Lilly; Merck; Merrimack; Novartis; OSI Pharmaceuticals; Pfizer; Roche/Genentech; Sanofi
Research Funding - National lung partnership; NCI
William Pao
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; MolecularMD; Symphony Evolution
Research Funding - AstraZeneca; Enzon; Symphogen; Xcovery